Experimental mRNA therapy targets multiple autoimmune diseases in first human trial
NCT ID NCT06801119
Summary
This early-stage study is testing a new mRNA-based therapy called HN2301 in people with autoimmune diseases including lupus, scleroderma, and rheumatoid arthritis. The main goal is to check if the treatment is safe and well-tolerated in 30 participants who have active disease despite standard treatments. Researchers will also look for early signs that the therapy might help control disease activity over 12 months of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.